Marta Herrera Soto, MD
Internal Medicine · Rockledge, FLNPI 1346561552
Payments from drug & device makers
Across 347 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$553
- Novo Nordisk$541
- Lilly USA, LLC$503
- Sanofi-aventis U.S. LLC$502
- Boehringer Ingelheim$461
- plus $2K from 28 others
What the payments were for
- Food & beverage$5,74699%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 90 | $1,189 |
| AstraZeneca | 30 | $553 |
| Novo Nordisk | 27 | $541 |
| Lilly USA, LLC | 32 | $503 |
| Sanofi-aventis U.S. LLC | 27 | $502 |
| Boehringer Ingelheim | 27 | $461 |
| Pfizer | 22 | $343 |
| Bayer | 11 | $202 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $176 |
| Exact Sciences | 9 | $152 |
| Merck | 8 | $141 |
| Zimmer Biomet | 1 | $137 |
| GSK | 7 | $112 |
| Abbott | 4 | $85 |
| Amarin Pharma, Inc. | 4 | $82 |
| Amgen | 5 | $75 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $66 |
| Biohaven Pharmaceuticals, Inc. | 4 | $61 |
| IBSA Pharma Inc. | 4 | $56 |
| Paratek Pharmaceuticals, Inc. | 3 | $51 |
| Dexcom, Inc. | 2 | $34 |
| Novartis | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Almatica Pharma LLC | 2 | $28 |
| Scilex Pharmaceuticals Inc. | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
| BD | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Vivus LLC | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Polaris 4.75 Spinal System$137
- Wegovy$125
How this compares
$5,795 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SimponiGolimumab | 12 | $143,644 |
| JardianceEmpagliflozin | 75 | $96,557 |
| EliquisApixaban | 64 | $77,189 |
| OzempicSemaglutide | 39 | $72,958 |
| MounjaroTirzepatide | 54 | $57,411 |
| Tresiba Flextouch U-200Insulin Degludec | 55 | $50,666 |
| KerendiaFinerenone | 51 | $49,512 |
| TrulicityDulaglutide | 30 | $42,022 |
| JanuviaSitagliptin Phosphate | 25 | $39,136 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $36,368 |
| FarxigaDapagliflozin Propanediol | 31 | $32,580 |
| LinzessLinaclotide | 28 | $25,067 |
| Tresiba Flextouch U-100Insulin Degludec | 36 | $21,353 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $14,919 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 386 | $13,836 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat, Synjardy Xr, Spiriva Respimat | $461 | $117,171113 claims |
| Lilly USA, LLCMounjaro, Trulicity | $503 | $99,43384 claims |
| PfizerEliquis | $343 | $77,18964 claims |
| Novo NordiskOzempic | $541 | $72,95839 claims |
| BayerKerendia | $202 | $49,51251 claims |
| AstraZenecaFarxiga, Symbicort | $553 | $47,49965 claims |
| MerckJanuvia | $141 | $39,13625 claims |
| AbbVieLinzess, Synthroid | $1,189 | $28,62366 claims |
| GSKTrelegy Ellipta | $112 | $13,11520 claims |
| Sanofi-aventis U.S. LLCAmbien | $502 | $6,81211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Rockledge
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.